Candel Therapeutics, Inc. (CADL)
NASDAQ: CADL · Real-Time Price · USD
8.75
-1.21 (-12.15%)
At close: Dec 20, 2024, 4:00 PM
8.65
-0.10 (-1.14%)
After-hours: Dec 20, 2024, 7:52 PM EST
Candel Therapeutics Employees
Candel Therapeutics had 42 employees as of December 31, 2023. The number of employees decreased by 34 or -44.74% compared to the previous year.
Employees
42
Change (1Y)
-34
Growth (1Y)
-44.74%
Revenue / Employee
n/a
Profits / Employee
-$1,242,833
Market Cap
284.16M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 42 | -34 | -44.74% |
| Dec 31, 2022 | 76 | 11 | 16.92% |
| Dec 31, 2021 | 65 | 24 | 58.54% |
| Dec 31, 2020 | 41 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Revance Therapeutics | 597 |
| AirSculpt Technologies | 381 |
| NeuroPace | 171 |
| Acelyrin | 135 |
| Olema Pharmaceuticals | 74 |
| Jasper Therapeutics | 45 |
| Corvus Pharmaceuticals | 28 |
| Trevi Therapeutics | 25 |
CADL News
- 5 days ago - Candel Therapeutics Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares - GlobeNewsWire
- 8 days ago - Candel Therapeutics, 8x8 And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Benzinga
- 9 days ago - Candel Therapeutics Announces Pricing of Public Offering - GlobeNewsWire
- 9 days ago - Candel Therapeutics Announces $80 Million Proposed Public Offering - GlobeNewsWire
- 10 days ago - Candel Therapeutics: Surprising Win Puts Potential Drug Approval In Sight - Seeking Alpha
- 10 days ago - Candel Therapeutics Stock Surges Over 100% - Here's Why - Benzinga
- 10 days ago - Candel Therapeutics' cancer drug meets late-stage trial goals - Reuters
- 10 days ago - Candel Therapeutics Announces CAN-2409 Achieved Primary Endpoint in Phase 3 Prostate Cancer Trial, Showing Significantly Improved Disease-Free Survival - GlobeNewsWire